Role of tissue factor pathway inhibitor in hormone-induced venous thromboembolism

Abstract

Exposure to higher levels of steroid hormones, like that in pregnancy or during combined hormonal contraception, increases the risk of venous thromboembolism. Development of resistance to activated protein C (APC) thought to be the underlying pathomechanism of this prothrombotic state. This coagulation phenomena is largely to be explained by the hormone-induced impairment of the protein S/ tissue factor pathway inhibitor (TFPI) leading to a less efficient inactivation of factor Va and factor VIIIa by APC. APC resistance and decreased protein S/TFPI function were associated with the risk of first as well as recurrent venous thromboembolism. Preexisting disturbances in these pathways are likely to predispose to thrombosis during hormone exposure and can persist over years after the thrombosis event.Further studies are necessary to investigate the predictive value of forgoing APC resistance and decreased protein S/TFPI function or an excessive alteration in these parameters during hormone intake on the development of hormone-induced venous thromboembolism.

Plasma tissue factor pathway inhibitor levels in coronavirus disease 2019 patients: a systematic review and meta-analysis

“…Tissue factor pathway inhibitor (TFPI) is one of the major anticoagulant factors, which is typically found on the endothelial surface and plays a critical regulatory role in controlling inappropriate excess of clotting by modulation of tissue factor-induced coagulation [1–3]. It is a multivalent Kunitz-type protease inhibitor that forms a quaternary complex with factor VII active (FVIIa), tissue factor (TF), and FXa [2,3].…”